AR128082A1 - ANTICUERPOS CONTRA LA ESPÍCULA (S) DEL SARS-CoV-2 Y SU USO EN EL TRATAMIENTO DE COVID-19 - Google Patents

ANTICUERPOS CONTRA LA ESPÍCULA (S) DEL SARS-CoV-2 Y SU USO EN EL TRATAMIENTO DE COVID-19

Info

Publication number
AR128082A1
AR128082A1 ARP220103567A ARP220103567A AR128082A1 AR 128082 A1 AR128082 A1 AR 128082A1 AR P220103567 A ARP220103567 A AR P220103567A AR P220103567 A ARP220103567 A AR P220103567A AR 128082 A1 AR128082 A1 AR 128082A1
Authority
AR
Argentina
Prior art keywords
cov
covid
spine
treatment
antibodies against
Prior art date
Application number
ARP220103567A
Other languages
English (en)
Inventor
Gale Smith
Nita Patel
Original Assignee
Novavax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novavax Inc filed Critical Novavax Inc
Publication of AR128082A1 publication Critical patent/AR128082A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención proporciona anticuerpos que se unen a la proteína de la espícula (S) del SARS-CoV-2. La invención también se relaciona con composiciones farmacéuticas, composiciones inmunoterapéuticas y métodos que usan los anticuerpos mencionados anteriormente que se unen a la proteína de la espícula (S) del SARS-CoV-2. Reivindicación 26: Una molécula de ácido nucleico caracterizada porque codifica el anticuerpo o el fragmento de él de acuerdo con una cualquiera de las reivindicaciones 1 - 25. Reivindicación 27: Un vector de expresión caracterizado porque comprende el ácido nucleico de acuerdo con la reivindicación 26. Reivindicación 28: Una célula huésped caracterizada porque comprende el vector de expresión de acuerdo con la reivindicación 27.
ARP220103567A 2021-12-23 2022-12-23 ANTICUERPOS CONTRA LA ESPÍCULA (S) DEL SARS-CoV-2 Y SU USO EN EL TRATAMIENTO DE COVID-19 AR128082A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163293451P 2021-12-23 2021-12-23

Publications (1)

Publication Number Publication Date
AR128082A1 true AR128082A1 (es) 2024-03-20

Family

ID=86903822

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220103567A AR128082A1 (es) 2021-12-23 2022-12-23 ANTICUERPOS CONTRA LA ESPÍCULA (S) DEL SARS-CoV-2 Y SU USO EN EL TRATAMIENTO DE COVID-19

Country Status (3)

Country Link
AR (1) AR128082A1 (es)
TW (1) TW202346332A (es)
WO (1) WO2023122786A2 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013040358A2 (en) * 2011-09-14 2013-03-21 University Of Washington Through Its Center For Commercialization Assays and compositions for detection of agr2
US9624272B2 (en) * 2013-03-14 2017-04-18 University Of Washington Through Its Center For Commercialization Polypeptides for treating and/or limiting influenza infection
CN106810609A (zh) * 2015-11-27 2017-06-09 苏州君盟生物医药科技有限公司 抗pcsk9抗体及其应用
US11359025B2 (en) * 2016-10-16 2022-06-14 Cantargia Ab Anti-IL1-RAP antibodies
WO2021212049A2 (en) * 2020-04-17 2021-10-21 Washington University Anti-sars-cov-2 monoclonal antibodies
CN115916256A (zh) * 2020-04-24 2023-04-04 单细胞科技公司 抗sars冠状病毒2型刺突蛋白抗体
WO2021228904A1 (en) * 2020-05-11 2021-11-18 Academisch Medisch Centrum Neutralizing antibodies binding to the spike protein of sars-cov-2 suitable for use in the treatment of covid-19, compositions comprising the same and uses thereof
WO2021239014A1 (en) * 2020-05-26 2021-12-02 Single Cell Technology, Inc. Anti-sars coronavirus-2 spike protein antibodies

Also Published As

Publication number Publication date
WO2023122786A2 (en) 2023-06-29
WO2023122786A3 (en) 2023-09-14
TW202346332A (zh) 2023-12-01

Similar Documents

Publication Publication Date Title
CY1125429T1 (el) Μουτεϊνες ιντερλευκινης-21 και μεθοδοι θεραπευτικης αγωγης
EA202091710A1 (ru) Антитела против cd73 и способы их применения
CO2018012415A2 (es) Proteínas de unión específica y usos de las mismas
CY1123657T1 (el) Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1
CY1113089T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα σε ειδικο προστατικο μεμβρανικο αντιγονο (psma)
BR112016013347A8 (pt) anticorpo monoclonal humano neutralizante anti-il-33,composição farmacêutica,inibidor da expressão de citocinas,epitopo,molécula de ácido nucleico,vetor,célula hospedeira,método de produção e uso dos mesmos.
EA201791961A1 (ru) Антитела, специфичные к cd47 и pd-l1
BR112021005769A2 (pt) proteínas de ligação a dll3 e métodos de uso
EA201791666A1 (ru) Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123
PE20190398A1 (es) Anticuerpos nuevos que se unen especificamente a los epitopos del virus del zika y usos de los mismos
CY1117036T1 (el) Ανθρωπινα αντισωματα που προσδενουν cxcr4 και χρησεις αυτων
EA201890169A1 (ru) Тау-связывающие антитела
BRPI0619595B8 (pt) anticorpo neutralizante, sequência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para a produção de um anticorpo, composição farmacêutica, e, uso de um anticorpo neutralizante humanizado
BRPI0717768B8 (pt) anticorpo, epítopo, sequência de dna isolada, vetor de clonagem ou expressão, processo para a produção do anticorpo, composição farmacêutica, e, uso de um anticorpo
PE20210375A1 (es) Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
BR112022000371A2 (pt) Anticorpos claudin18 e métodos de tratamento contra câncer
CL2008002444A1 (es) Anticuerpo o fragmento del mismo que se une a la proteina c-fms humana; molecula de acido nucleico que la codifica; vector y celula huesped; metodo de elaboracion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir una condicion asociada con c-fms en un paciente.
NO20083053L (no) Humane monoklonale antistoffer mot O8E
PE20050712A1 (es) Anticuerpos rg1
BR112019005129A2 (pt) anticorpos anti-pd-1
EA201892774A1 (ru) Антитела
CO2023009615A2 (es) Anticuerpos multiespecíficos que tienen especificidad para il-4r e il-31
WO2021227307A8 (zh) 抗cd73抗体及其用途
AR109683A1 (es) Anticuerpos contra el factor xi y sus usos